Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Healthy Volunteer
The Contrast-Enhanced Spectral Mammography Imaging Screening Trial CMIST aims to find out if dual-energy contrast-enhanced spectral mammography CESM can detect more breast cancers with fewer false positives than digital breast tomosynthesis DBT in women with dense breasts. The study evaluates these two imaging methods at baseline and after one year to improve breast cancer screening accuracy in women aged 45 to 74 with dense breast tissue. Participants will receive both standard DBT and CESM screenings on the same day at the start of the study and again after one year. At the two-year point, participants will return to their usual mammography screening without CESM. The study involves routine imaging procedures without additional treatments, aiming to compare the diagnostic performance of these imaging techniques. Throughout the study, participants will have baseline and one-year imaging visits, followed by a two-year follow-up contact to confirm no interval breast cancer diagnosis. Researchers will monitor cancer detection rates at baseline and recall rates at one year. Safety questions about adverse events will be asked during follow-up, and participants usual breast cancer screening care will continue after study completion.
Actively Recruiting
Healthy Volunteer
Researchers are collecting Optical Coherence Tomography OCT data to study both normal and diseased eyes, including conditions such as retinal disease, glaucoma, and corneal disease. This observational study aims to gather detailed imaging information to better understand these eye conditions using the A10900 OCT device. Participants will undergo OCT imaging with the A10900 device, which captures detailed pictures of the eyes structures. The study includes groups with retinal disease, glaucoma, corneal disease, and healthy eyes. Each participant will have OCT scans taken to collect data relevant to their specific eye condition or normal eye status. During the study, participants will have their eyes scanned with OCT and may undergo vision tests like best-corrected visual acuity BCVA. Researchers will count the number of OCT scans performed over one year to measure outcomes. Participants will be monitored for their ability to tolerate imaging and comply with study procedures. The study includes healthy volunteers and people with various eye diseases, with ongoing safety and imaging quality assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an online intervention designed to support conversations between fathers and their high-school-aged teens about sex and relationships. This pilot study aims to assess the programs acceptability, feasibility, and early effects using Social Cognitive Theory and an Intervention Mapping approach. The study will involve 50 father-teen pairs and will help determine if a larger-scale study is justified. The intervention includes three weekly online modules delivered via Qualtrics and Zoom, featuring separate lessons for fathers and teens, joint father-teen activities, and weekly father support group sessions. Each module lasts one week and includes self-paced lessons, interactive activities, and scheduled group meetings to encourage discussion and learning. Participants will receive reminders and have access through computer or tablet. Participants will complete surveys before and after the intervention to measure changes in sexual health knowledge, communication self-efficacy, and comfort discussing these topics with family. Feasibility is tracked through enrollment, retention, lesson participation, and feedback collected via surveys and interviews. The study includes detailed assessments of program acceptability and participant experiences, with involvement lasting approximately six weeks.
Actively Recruiting
Researchers are evaluating a modified regimen of ublituximab for adults with relapsing multiple sclerosis RMS in this phase 3b study. The study aims to assess the medicines impact on brain lesions visible on MRI scans and its pharmacokinetics, particularly in participants who had limited benefit from prior anti-CD20 therapies. The trial includes three parts Part A is open-label and single-arm, Part B is randomized, double-blind, and placebo-controlled, and Part C is open-label and single-arm. Participants receive ublituximab through intravenous infusions, with dosing schedules varying by study part. In Part A, infusions occur on Day 1 of Week 1, Day 15 if applicable, and at Week 24. In Part B, participants receive either 600 mg ublituximab on Week 1 Day 1, placebo on Day 15, and 450 mg ublituximab at Week 24, or 150 mg ublituximab on Week 1 Day 1 followed by 450 mg on Day 15 and Week 24. Part C participants receive 150 mg on Week 1 Day 1 and 450 mg on Day 15 and Week 24. During the study, participants are monitored for changes in T1 Gadolinium-enhancing lesions on MRI from baseline to Week 48, infusion-related reactions, treatment satisfaction, and pharmacokinetics over 16 weeks. Safety and efficacy assessments include neurological stability, clinical exams, and questionnaires. The total study duration extends to at least 48 weeks, with detailed follow-up and monitoring to evaluate treatment impact and participant health.